Withdrawn; WBA will revise the publicly available report.
Proposal urging Board of Directors (“Board”) to report to shareholders by June 30, 2020 describing the corporate governance changes Walgreens has implemented since 2012 to more effectively monitor and manage financial and reputational risks related to the opioid crisis, including whether and how the Board oversees Walgreens’ opioid-related programs and AmerisourceBergen’s opioid-related risks, and whether and how Walgreens has changed senior executive incentive compensation arrangements.
WBA will revise the publicly available report t state that (i) WBA currently has a contractual right to designate 1 director to the ABC BOD, (ii) WBA has designated Ornella Barra to serve on the ABC BOD, and (iii) WBA will be entitled to designated a total of 2 directors to the ABC BOD if WBA’s stock ownership increases above a certain threshold. WBA will reconsider the location where the Report is posted on their website.
We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes. You can consent to the use of such technologies by using the “Accept” button, by closing this notice, by scrolling this page, by interacting with any link or button outside of this notice or by continuing to browse otherwise.